# Pizarra — PT-pseudo_06b319f42fcb (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_06b319f42fcb
Task: 1

Encounter: Urology - outpatient on 24 Feb 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 13.5 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.452 ng/mL²
  - PSA velocity: 1.92 ng/mL/yr
  - Prior PSA: 12.3 ng/mL
  - Prostate volume: 29.86 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8947026 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, COPD, Chronic kidney disease, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, COPD, Chronic kidney disease, Benign prostatic hyperplasia
  - Current medication: valsartan, metoprolol, tiotropium, salbutamol PRN, tamsulosin
  - Allergies: NSAIDs
  - Additional notes: PSA 13.5 ng/mL. PI-RADS 5. PSAD 0.45. Prostate volume 30 mL. csPCa 0.89.

Vitals: weight 84 kg, height 186 cm, BMI 24.3, BP 129/83 mmHg, HR 64 bpm. Smoking: Non-smoker.

Chief complaint: Current clinical focus centers on reassessing known ISUP GG1 pathology alongside a PSA reading of 13.5 ng/mL.

History: A retired civil servant first entered investigation for elevated PSA markers in early 2023. The individual is married and shares a home with his partner. He maintains a strictly non-smoking status. Medical background includes hypertension, chronic obstructive pulmonary disease, chronic kidney disease, and benign prostatic hyperplasia. Current pharmacotherapy consists of valsartan, metoprolol, tiotropium, and salbutamol on a PRN basis, alongside tamsulosin for lower urinary tract symptoms. Cardiology and pulmonary assessments have recently confirmed stable parameters. Daily mobility includes a twenty-minute walking routine, though he experiences intermittent fatigue that does not correlate with physical activity. Lower urinary tract symptom severity registers at an IPSS score of 13. Two systematic biopsies performed in 2023 and 2024 both revealed Gleason 3+3 disease, placing him under ongoing surveillance. A routine colonoscopy and a recent influenza vaccination occurred without complication. He reports no alterations in bowel habits, unexplained weight shifts, hematuria, pelvic discomfort, or bone pain. Overall systemic health remains steady.

Physical examination: DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: absent. The gland presents with symmetrical enlargement and lacks any palpable nodules. Systemic assessment shows stable vital signs, recording a blood pressure of 129/83 mmHg and a regular heart rate of 64 bpm. Abdominal palpation yields no masses, and peripheral lymphatic examination remains entirely unremarkable.

Patient info: retired civil servant; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 20 min/day; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Pulmonary function test — known COPD follow-up; Gastroenterology — surveillance colonoscopy; GP practice nurse — flu vaccination.
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.61 +/- 0.20   (95% CI 0.21-0.94)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 5.6 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=13.5, age=66.0, psad=0.452, dre_ord=0.0, vol=29.86, n_pmhx=4.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (1.92 ng/mL/yr) against the prior PSA (12.3 ng/mL) and the current PSA (13.5 ng/mL), which suggests a rapid rise. It also could not incorporate the specific details from the mpMRI report (beyond the PI-RADS 5) or the full laboratory panel, which might contain markers influencing the csPCa probability.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests BIOPSY with a wide uncertainty interval (0.61 +/- 0.20), indicating it is in the 'discuss' tier. A failure mode is the high csPCa predicted probability (0.8947026) combined with a PI-RADS 5, which might strongly suggest biopsy, but this is counterbalanced by the prior biopsy being 'Positive'. Another failure mode is the DRE being 'Normal' despite the high PSA and PI-RADS 5, which could indicate a situation where the biopsy decision hinges entirely on the prior pathology status, which the prior did not fully integrate.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details specific features (e.g., clinically significant extension, atypical glands) that contradict the PI-RADS 5, it could shift the decision away from biopsy.
  <document> PSA history (trend) -> If the trend shows a plateau or decline despite the high current PSA, it would reduce the urgency for biopsy.
  <document> previous GP / urology consultation notes -> These notes might clarify the clinical context of the prior positive biopsy and the rationale for the current re-evaluation.
  <document> laboratory results (full panel) -> This could reveal other markers that modify the risk assessment beyond the structured panel inputs.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_06b319f42fcb", "radiology_report": "Subject: Prostate mpMRI | Date: 10 February 2025 | Department: Radiology\n\nClinical indication: A 66-year-old gentleman presents for re-evaluation of suspected clinically significant prostate cancer, following previous positive biopsies. Current PSA measures 13.5 ng/mL.\n\nFINDINGS:\nThe gland occupies 29.86 mL. T2-weighted sequences highlight a 14 x 12 x 10 mm hypointense focus within the right mid-gland peripheral zone. Diffusion-weighted imaging demonstrates pronounced restriction with correspondingly low ADC values. Dynamic contrast-enhanced sequences reveal early focal enhancement within that same area. No extraprostatic extension, seminal vesicle invasion, or suspicious pelvic lymphadenopathy is identified.\n\nIMPRESSION:\nPI-RADS 5 lesion in the right mid-gland peripheral zone.\nProstate volume 29.86 mL, PSAD 0.452 ng/mL/mL.\ncsPCa predicted probability 0.8947026."}

  **psa_trend**
  {"case_id": "PT-pseudo_06b319f42fcb", "psa_trend": [{"date": "Mar 2023", "val": 4.2}, {"date": "Nov 2023", "val": 6.2}, {"date": "Jun 2024", "val": 9.1}, {"date": "Feb 2025", "val": 13.5}]}

  **previous_notes**
  {"case_id": "PT-pseudo_06b319f42fcb", "previous_notes": [{"date": "27 Oct 2024", "author": "Dr. F. de Boer (GP)", "text": "Clinical review focused on a progressive PSA trajectory. A biopsy conducted in 2023 established ISUP GG1 disease. Subsequent testing in June 2024 yielded a PSA reading of 12.3 ng/mL, which triggered further urological referral. The individual remains on tamsulosin for lower urinary tract symptoms and maintains stable COPD management via tiotropium."}, {"date": "29 Jun 2024", "author": "Dr. F. de Boer (GP)", "text": "Initial PSA elevation noted during a March 2023 consultation led to serial monitoring. A November 2023 recheck returned 17.8 ng/mL, prompting a transrectal ultrasound-guided sampling. Pathology from that session returned Gleason 3+3, ISUP GG 1. Routine laboratory rechecking was scheduled alongside standard symptom tracking."}]}

  **laboratory_results**
  {"case_id": "PT-pseudo_06b319f42fcb", "laboratory_results": [{"name": "PSA", "val": "13.5 ng/mL", "date": "19 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "2.59 ng/mL", "date": "19 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "19%", "date": "19 Jan 2025", "flag": ""}, {"name": "Haemoglobin", "val": "13.8 g/dL", "date": "19 Jan 2025", "flag": ""}, {"name": "WBC", "val": "4.4 x10^9/L", "date": "19 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "234 x10^9/L", "date": "19 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "129 umol/L", "date": "19 Jan 2025", "flag": "H"}, {"name": "eGFR", "val": "<60 mL/min/1.73m2", "date": "19 Jan 2025", "flag": "L"}, {"name": "Testosterone", "val": "16.4 nmol/L", "date": "19 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "62 U/L", "date": "19 Jan 2025", "flag": ""}, {"name": "LDH", "val": "228 U/L", "date": "19 Jan 2025", "flag": ""}, {"name": "HbA1c", "val": "5.7 %", "date": "19 Jan 2025", "flag": ""}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PI-RADS 5 lesion in the right mid-gland peripheral zone
  - PSA velocity of 1.92 ng/mL/yr (based on trend data)
  - csPCa predicted probability of 0.8947026

  AGAINST sampling this patient now:
  - Prior biopsy was Positive (Gleason 3+3, ISUP GG1)
  - DRE findings are Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the high-risk MRI finding (PI-RADS 5) and the rising PSA velocity, which aligns with the statistical prior's suggestion to biopsy. This contradicts the prior positive biopsy result, suggesting the current findings warrant re-evaluation.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly points toward sampling due to the high-risk PI-RADS 5 lesion and the rising PSA velocity of 1.92 ng/mL/yr. This finding overrides the prior positive biopsy result, suggesting the current imaging and trend warrant re-evaluation. The decision is driven by the PI-RADS 5 score and the PSA velocity, which align with the statistical prior's suggestion to biopsy.

Variables that carried weight: bx=decisive, dre=noted, psa=decisive, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
